Sedat Altuǧ

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Dae Ho Lee, Jung Shin Lee, Sang‐We Kim et al. · European Journal of Cancer · 2013 · 78 citations

Second-line Treatment, Medicine, Pharmacology +7

Evidence for the involvement of peroxynitrite in ischaemic preconditioning in rat isolated hearts

Sedat Altuǧ, Abdullah Tuncay Demiryürek, Kathleen A. Kane et al. · British Journal of Pharmacology · 2000 · 72 citations · Full text

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

James Chih‐Hsin Yang, Jin Hyoung Kang, Tony Mok et al. · European Journal of Cancer · 2014 · 46 citations

Medicine, Pathology, Bronchial Neoplasm +6

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

Luis G. Paz-Ares, Sedat Altuǧ, A. Thareau Vaury et al. · BMC Cancer · 2010 · 35 citations · Full text

Patient attitudes towards chemotherapy as assessed by patient versus physician: A prospective observational study in advanced non-small cell lung cancer

Da-Tong Chu, Sang-We Kim, Han-Pin Kuo et al. · Lung Cancer · 2007 · 35 citations

Oncology, Health Communication, Cancer Management +8